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Abstract
PIK3CA, which encodes the p110a catalytic subunit of PI3Ka, is one of the
most frequently altered oncogenes in colon cancer (CC), but its prognostic
value is still a matter of debate. Few reports have addressed the association
between PIK3CA mutations and survival and their results are controversial. In
the present study, we aimed to clarify the prognostic impact of PIK3CA muta-
tions in stage I–III CC according to mismatch repair status. Fresh frozen tissue
samples from two independent cohorts with a total of 826 patients who under-
went curative surgical resection of CC were analyzed for microsatellite instabil-
ity and screened for activating point mutations in exon 9 and 20 of PIK3CA by
direct sequencing. Overall, 693 tumors (84%) exhibited microsatellite stability
(MSS) and 113 samples (14%) harbored PIK3CA mutation. In the retrospective
training cohort (n = 433), patients with PIK3CA-mutated MSS tumors
(n = 47) experienced a significant increased 5-year relapse-free interval com-
pared with PIK3CA wild-type MSS tumors (n = 319) in univariate analysis
(94% vs. 68%, Log-rank P = 0. 0003) and in multivariate analysis (HR = 0.12;
95% confidence interval, 0.029–0.48; P = 0.0027). In the prospective validation
cohort (n = 393), the favorable prognostic impact of PIK3CA mutations in
MSS tumors (n = 327) was confirmed (83% vs. 67%, Log-rank P = 0.04). Our
study showed that PIK3CA mutations are associated with a good prognosis in
patients with MSS stage I–III CC.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Introduction
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR sig-
naling pathway is critical for cell growth, survival, and
malignant transformation. It is inappropriately activated
in many different cancer types [1]. Activation is often
mediated by mutations occurring in PIK3CA, which
encodes the p110a catalytic subunit of a heterodimeric
class IA PI3K called PI3Ka. This gene is one of the most
frequently mutated genes (16%) in colorectal cancer
(CRC), after notably TP53 (51%), APC (37%), and KRAS
(36%) [2].
In the signal transduction, after ligand binding to a
tyrosine kinase receptor, activated PI3Ka phosphorylates
phosphatidylinositol 4,5-bisphosphate (PIP2) at the
30-position of the inositol ring, allowing the generation of
phosphatidylinositol 3,4,5-triphosphate (PIP3). This
second messenger binds and recruits the 3-phosphoinosi-
tide-dependent protein kinase-1 (PDK1), which thereafter
activates AKT/PKB, a serine/threonine kinase involved in
regulating many biological processes such as cell survival,
growth, and metabolism [3]. There are three major muta-
tional hotspots (at codons 542, 545, and 1047) in exons 9
and 20 of PIK3CA, partially encoding the helical domain
and the C-terminal kinase domain of the protein, respec-
tively [4]. Activating point mutations in these amino-acid
residues elevate the enzymatic activity of PI3K and con-
tribute to tumorigenesis through cell proliferation,
decreased apoptosis and autophagy, loss of contact inhibi-
tion, induction of angiogenesis, and increased tumor
invasion [5–7].
As one of the most commonly deregulated pathways in
solid human cancers, targeting the PI3K/AKT/mTOR
pathway could be of important therapeutic interest [8].
Indeed, a number of PI3K or dual PI3K-mTOR inhibitors
have been, or will soon be, introduced into clinical trials
as antitumor agents for the treatment of CRC and other
malignancies [9–11]. Preclinical studies demonstrated that
PIK3CA mutations predict response to these agents, pre-
sumably due to oncogene addiction [12–15]. However,
prognosis of CRC patients harboring PIK3CA mutation
remains unclear and results from previous studies dealing
with this issue seem conflicted [16–22]. Thus, the prog-
nostic role of PIK3CA as an independent predictor of
recurrence and/or survival in patients with CRC remains
to be determined.
The discrepancy of published results could be in part
explained by the well-known molecular heterogeneity of
CRC. Among the different individualized molecular sub-
groups, tumors with microsatellite instability (MSI)
accounts for ~15% of all CRCs and are characterized by
defective DNA mismatch repair and genomic instability.
The remaining 85% of microsatellite stable (MSS) CRC
display chromosomal instability resulting in hyperploidy
associated with allelic losses. Both groups show specific
particularities in terms of natural history, tumor location,
pathological features, mechanisms of carcinogenesis, and
genetic mutation patterns [23].
The aim of this multicenter study was to investigate
the prognostic value of PIK3CA mutations in nonmeta-
static colon cancer (CC) according to MSI status.
Material and Methods
Study population
The French national “Cartes d’Identite des Tumeurs”
(CIT) program involved a multicenter cohort of 782
patients with stage I–IV CRC who underwent surgery
between 1987 and 2007 in seven centers. Fresh frozen pri-
mary tumor tissue samples were retrospectively collected.
Clinicopathological data were extracted from the medical
charts and centrally reviewed for all patients. This retro-
spective cohort was used as a training cohort.
For validation purpose, the prospective cohort from
the population-based registry of digestive cancer in the
Co^te-d’Or area (Burgundy, France) previously describe
elsewhere was used [24, 25]. Tumor samples from this
validation patient cohort included all CC resected
between 1998 and 2002 for which frozen tissue material
was available and suitable for molecular analysis.
Patients with rectal cancer (located within 15 cm from
the anal verge), distant metastasis or who received neoad-
juvant therapy (either chemotherapy and/or radiotherapy)
were excluded from analysis. Thus, only stage I–III CC
according to the 7th edition of the AJCC/UICC tumor-
node-metastasis (TNM) classification operated in a cura-
tive intent were further considered for evaluation [26].
PIK3CA status had also to be determined for each sample.
This study was approved by the Institutional Review
Boards of all participating centers.
Mutation analysis
Genomic DNA was extracted from fresh frozen tissues.
Exons 9 and 20 of the PIK3CA gene were selected for
screening by direct Sanger sequencing on both strands
because of the high frequency of somatic mutations known
to be clustered in these regions [4]. All samples found to be
mutated were PCR-amplified and sequenced in a second,
independent experiment. PCR conditions for amplification
and primer sequences are available upon request.
The seven most common somatic mutations of KRAS
located within codon 12 (G12D, G12V, G12C, G12A,
372 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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G12S, and G12R) and codon 13 (G13D), as well as BRAF
V600E mutation, were assessed by allelic discrimination
using TaqMan-specific probes as previously described
[27].
Microsatellite status and CpG island
methylator phenotype analysis
In the retrospective CIT cohort, MSI status was assessed
according to the panel of five microsatellites approved by
the consensus conference (D2S123, D5S346, D17S250,
BAT25, and BAT26) [28]. In the validation cohort, MSI
status was determined as previously described [29].
We used the MSP (gel-based methylation-specific PCR)
method with the panel of the five markers CACNA1G,
IGF2, NEUROG1, RUNX3, and SOCS1 to determine
CpG island methylator phenotype (CIMP) status [30].
After DNA bisulfite treatment, two multiplex methyla-
tion-specific PCR were performed. Capillary electrophore-
sis on automatic sequencer (ABI 3130 Genetic analyzer;
Applied Biosystems, Foster City, CA, USA) was used for
fragment analysis. The methylation status of each gene
was determined as detailed by Weisenberg and colleagues
[29]. Methylator phenotype-positive cases (CIMP+) were
defined as those with ≥3 methylated promoters and
CIMP—cases as those with <2 methylated promoters.
Statistic analysis
The distribution of patient and tumor characteristics was
compared across cohorts by the Chi-squared test or the
Fisher’s exact test for categorical data, as appropriate, and
by the Welch’s t-test for continuous data.
Relapse-free interval (RFI) was defined as the time
from CC resection to locoregional and/or distant recur-
rence, whichever came first. Patients alive with no evi-
dence of disease at last follow-up and patients who died
without any recurrence were censored. Overall survival
(OS) was defined as the period of time between CC sur-
gery and death. Survival curves were plotted according to
the method of Kaplan and Meier and differences between
survival distributions were assessed by the log-rank test.
Univariate and multivariate models for survival analysis
were computed using Cox proportional hazards regres-
sion. All the variables that were significant in univariate
analysis were included in the multivariate model. The
proportional hazards assumptions were tested to examine
the appropriateness of the models.
All P-values were two-sided and statistical significance
was assumed for P ≤ 0.05. All statistical analyses were
performed using the R statistical environment (http://
www.R-project.org). Survival analyses were performed
using the R package survival.
Results
Patient characteristics
A total of 826 samples from stage I–III CC with successful
mutation analysis for PIK3CA were obtained from both
cohorts (n = 433 in the training cohort and n = 393 in
the validation cohort). Patients’ characteristics are
depicted in Table 1. Overall, 133 tumors exhibited MSI
phenotype (67 [15%] in the training cohort and 66
[17%] in the validation cohort, P = 0.67). Among MSS
tumors, patients included in the validation cohort were
significantly older (69 vs. 73 years, P = 0.00021), had less
advanced stage (45% vs. 35% for stage III, P = 0.015)
and were less likely to receive adjuvant chemotherapy
(45% vs. 32%, P = 0.00071), as compared with the train-
ing cohort. Among MSI tumors, patients in the validation
cohort were significantly older (74 vs. 80 years,
P = 0.0016). Significant more patients had a Lynch syn-
drome in the training cohort (4% vs. 1%, P = 0.0087).
Only one patient, included in the validation cohort, had a
familial adenomatous polyposis.
PIK3CA mutations analysis and associations
with other molecular and
clinicopathological features
Among the 826 tumors suitable for PIK3CA, 113 (14%)
tumors displayed a mutation in exon 9 and/or 20 (59 in
the training cohort and 54 in the validation cohort). Most
PIK3CA mutations were located in exon 9 with 38 tumors
in the training cohort (64% of the mutated samples) and
32 tumors in the validation cohort (59% of the mutated
samples). PIK3CA mutations in exon 20 were detected in
6% of the tumors in both cohorts. Only four tumors
(three MSS tumors and one MSI tumor, all in the train-
ing cohort) harbored PIK3CA mutation in both exons 9
and 20, which accounted for 0.5% of all studied samples
and 4% of all mutated samples (Table 2).
The determination of KRAS and BRAF mutational sta-
tus could be ascertained for 817 (99%) and 780 (94%)
tumors, respectively (Table 3). In the whole population,
we identified KRAS mutation at codon 12 or 13 and
V600E BRAF mutation in 37% and 11% of cases, respec-
tively, with no statistical difference between the two
cohorts, either globally or according to MSI status. As
expected, KRAS and BRAF mutations were mutually
exclusive. Concomitant PIK3CA and KRAS mutations
were found in 55 tumors (7%), whereas only 11 tumors
(1%) were mutated for both PIK3CA and BRAF.
We assessed the relationship between PIK3CA mutation
and clinicopathological and molecular features in each
cohort according to MSI status (Table 4). The frequency
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 373
G. Manceau et al. PIK3CA Mutations in Microsatellite Stable Colon Cancer
T
a
b
le
1
.
C
lin
ic
al
an
d
p
at
h
o
lo
g
ic
al
ch
ar
ac
te
ri
st
ic
s
o
f
p
at
ie
n
ts
ac
co
rd
in
g
to
m
ic
ro
sa
te
lli
te
st
at
u
s
in
th
e
tw
o
co
h
o
rt
s.
C
lin
ic
al
o
r
p
at
h
o
lo
g
ic
al
fe
at
u
re
s
A
ll
ca
se
s
n
(%
)
To
ta
l
C
IT
(%
)
To
ta
l
D
ijo
n
(%
)
P
va
lu
e
M
SS
C
IT
(%
)
M
SS
D
ijo
n
(%
)
P
va
lu
e
M
SI
C
IT
(%
)
M
SI
D
ijo
n
(%
)
P
va
lu
e
G
en
d
er
Fe
m
al
e
8
2
6
3
6
1
(4
4
)
1
8
9
(4
4
)
1
7
2
(4
4
)
0
.9
7
1
5
6
(4
3
)
1
3
0
(4
0
)
0
.4
9
3
3
(4
9
)
4
2
(6
4
)
0
.1
3
M
al
e
4
6
5
(5
6
)
2
4
4
(5
6
)
2
2
1
(5
6
)
2
1
0
(5
7
)
1
9
7
(6
0
)
3
4
(5
1
)
2
4
(3
6
)
A
g
e
(y
ea
rs
)1
8
2
6
8
2
6
6
9
[2
4
–9
6
]
7
3
[3
3
–9
5
]
1
.6
9
1
0
6
6
9
[2
5
–9
6
]
7
3
[3
6
–9
5
]
0
.0
0
0
2
1
7
4
[2
4
–9
2
]
8
0
[3
3
–9
1
]
0
.0
0
1
6
Tu
m
o
r
lo
ca
ti
o
n
2
D
is
ta
l
8
2
6
4
7
2
(5
7
)
2
4
9
(5
8
)
2
2
3
(5
7
)
0
.8
8
2
3
4
(6
4
)
2
1
4
(6
5
)
0
.7
4
1
5
(2
2
)
9
(1
4
)
0
.2
8
Pr
o
xi
m
al
3
5
4
(4
3
)
1
8
4
(4
2
)
1
7
0
(4
3
)
1
3
2
(3
6
)
1
1
3
(3
5
)
5
2
(7
8
)
5
7
(8
6
)
TN
M
st
ag
e
I
8
2
6
7
6
(9
)
3
3
(8
)
4
3
(1
1
)
0
.0
0
5
2
2
5
(7
)
3
5
(1
1
)
0
.0
1
5
8
(1
2
)
8
(1
2
)
0
.2
3
II
4
3
1
(5
2
)
2
1
1
(4
9
)
2
2
0
(5
6
)
1
7
5
(4
8
)
1
7
6
(5
4
)
3
6
(5
4
)
4
4
(6
7
)
III
3
1
9
(3
9
)
1
8
9
(4
4
)
1
3
0
(3
3
)
1
6
6
(4
5
)
1
1
6
(3
5
)
2
3
(3
4
)
1
4
(2
1
)
A
d
ju
va
n
t
C
T
N
o
8
2
3
5
4
0
(6
6
)
2
5
7
(5
9
)
2
8
3
(7
2
)
0
.0
0
0
1
4
2
0
3
(5
5
)
2
2
2
(6
8
)
0
.0
0
0
7
1
5
4
(8
2
)
6
1
(9
2
)
0
.1
2
Y
es
2
8
3
(3
4
)
1
7
5
(4
1
)
1
0
8
(2
8
)
1
6
3
(4
5
)
1
0
3
(3
2
)
1
2
(1
8
)
5
(8
)
A
ss
o
ci
at
ed
sy
n
d
ro
m
e
FA
P
8
0
6
1
(0
)
0
(0
)
1
(0
)
0
.0
0
8
7
0
(0
)
1
(0
)
0
.9
6
0
(0
)
0
(0
)
0
.0
0
0
2
Ly
n
ch
sy
n
d
ro
m
e
2
2
(3
)
1
8
(4
)
4
(1
)
0
(0
)
0
(0
)
1
8
(3
5
)
4
(6
)
N
o
n
e
7
8
3
(9
7
)
3
9
5
(9
6
)
3
8
8
(9
9
)
3
6
2
(1
0
0
)
3
2
6
(1
0
0
)
3
3
(6
5
)
6
2
(9
4
)
M
SS
,
m
ic
ro
sa
te
lli
te
st
ab
le
;
M
SI
,
m
ic
ro
sa
te
lli
te
in
st
ab
le
;
C
T,
ch
em
o
th
er
ap
y;
FA
P,
fa
m
ili
al
ad
en
o
m
at
o
u
s
p
o
ly
p
o
si
s.
1
M
ed
ia
n
[r
an
g
e]
.
2
Pr
o
xi
m
al
co
lo
n
in
cl
u
d
ed
ce
cu
m
,
as
ce
n
d
in
g
co
lo
n
,
h
ep
at
ic
fl
ex
u
re
,
an
d
tr
an
sv
er
se
co
lo
n
,
an
d
d
is
ta
l
co
lo
n
in
cl
u
d
ed
sp
le
n
ic
fl
ex
u
re
,
d
es
ce
n
d
in
g
,
an
d
si
g
m
o
id
co
lo
n
.
374 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PIK3CA Mutations in Microsatellite Stable Colon Cancer G. Manceau et al.
of PIK3CA mutations was not different between MSS and
MSI tumors (13% vs. 18%, P = 0.36 in the training
cohort and 13% vs. 17%, P = 0.57 in the validation
cohort). Among MSS tumors, PI3KCA mutations were
significantly more frequently located in the proximal
colon and associated with CIMP-positive tumors in the
training cohort (51% vs. 34%, P = 0.033 and 23% vs.
8%, P = 0.0063 respectively), and significantly more fre-
quent in female in the validation cohort (56% vs. 37%,
P = 0.032). A significant association between PIK3CA and
KRAS mutations (58% vs. 37%, P = 0.014) was found in
the validation cohort. Among MSI tumors, PIK3CA
mutations were significantly more frequent in patients
with early-stage disease in the training cohort (33% vs.
7% for stage I, P = 0.034).
PI3KCA mutation and patient survival
according to microsatellite status
We further examined the prognostic impact of PIK3CA
mutations in nonmetastatic CC after curative resection.
The median follow-up was 51 months (range,
1–192 months) in the training cohort and 61 months
(range, 1–143 months) in the validation cohort. The
5-year RFI was similar in the training cohort and in the
validation cohort, either globally (63% vs. 68%, P = 0.24),
and also within MSS and MSI tumors (63% vs. 66%,
P = 0.58 and 67% vs. 81%, P = 0.23, respectively).
Within the MSS CC subgroup of the training cohort,
patients with PIK3CA-mutated CC experienced a signifi-
cantly higher RFI than those without PIK3CA mutation
(5-year RFI 94% vs. 68%, Log-rank P = 0.0003; Hazard
Ratio [HR] = 0.12; 95% confidence interval [CI], 0.029–
0.48) on univariate analysis (Fig. 1A). This finding was
confirmed in the validation cohort (5-year RFI 83% vs.
67%, Log-rank P = 0.04; HR = 0.45; 95% CI, 0.21–0.97;
P = 0.04) (Fig. 1B). Similarly, OS was significantly higher
in patients with MSS PIK3CA-mutated CC than those
without PIK3CA mutation in the training cohort (5-year
OS 88% vs. 75%, Log-rank P = 0.04; HR = 0.43; 95% CI,
0.19–0.98) (Fig. 1C), and a strong tendency was also
observed in the validation cohort (5-year OS 77% vs.
62%, Log-rank P = 0.052; HR = 0.61, 95% CI, 0.37–1)
(Fig. 1D). A subgroup analysis according to TNM stage
(stage I–II and stage III) was also performed for RFI and
OS in both cohorts (Figs. S1 and S2).
We found that the type of PIK3CA mutation had no
differential effect on RFI (Fig. S3). Five-year RFI of
Table 2. Location of PIK3CA mutations according to microsatellite status in the two cohorts.
PIK3CA mutant types
CIT cohort Dijon cohort CIT cohort vs. Dijon cohort
MSS tumors (%) MSI tumors (%) MSS tumors (%) MSI tumors (%) P value MSS tumors P value MSI tumors
Exon 9 mutant 30 (64) 4 (33) 30 (70) 2 (18) 0.24 0.39
Exon 20 mutant 14 (30) 7 (58) 13 (30) 9 (82)
Exon 9 and 20 mutant 3 (6) 1 (8) 0 (0) 0 (0)
MSS, microsatellite stable; MSI, microsatellite instable.
Table 3. Molecular characteristics of colon cancers according to microsatellite status in the two cohorts.
Molecular
features
All
cases n (%)
Total
CIT (%)
Total
Dijon (%) P value
MSS
CIT (%)
MSS
Dijon (%) P value
MSI
CIT (%)
MSI
Dijon (%) P value
PIK3CA status
Mutant 826 113 (14) 59 (14) 54 (14) 0.96 47 (13) 43 (13) 0.99 12 (18) 11 (17) 0.97
Wild-type 713 (86) 374 (86) 339 (86) 319 (87) 284 (87) 55 (82) 55 (83)
KRAS status
Mutant 817 301 (37) 164 (38) 137 (35) 0.37 147 (40) 129 (40) 0.92 17 (27) 8 (12) 0.062
Wild-type 516 (63) 263 (62) 253 (65) 216 (60) 195 (60) 47 (73) 58 (88)
BRAF status
Mutant 780 85 (11) 35 (9) 50 (13) 0.12 7 (2) 12 (4) 0.37 28 (43) 38 (58) 0.11
Wild-type 695 (89) 353 (91) 342 (87) 316 (98) 315 (96) 37 (57) 27 (42)
CIMP status
CIMP 763 606 (79) 301 (81) 305 (78) 0.37 278 (90) 288 (88) 0.68 23 (37) 17 (26) 0.26
CIMP+ 157 (21) 71 (19) 86 (22) 32 (10) 38 (12) 39 (63) 48 (74)
MSS, microsatellite stable; MSI, microsatellite instable; CIMP, CpG island methylator phenotype.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 375
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patients with PIK3CA mutation in exon 9 or exon 20
were 94% and 93%, respectively, in the training cohort
(P = 0.50), and 79% and 92% (P = 0.37), respectively, in
the validation cohort. Notably, no recurrence occurred
for the three patients in the CIT cohort whose tumor har-
bored concomitant PIK3CA exon 9 and exon 20 muta-
tions.
We performed a multivariate analysis, adjusting for all
significant prognostic variables (P ≤ 0.05) including TNM
stage and PIK3CA mutations (Table 5). Risk of recurrence
remained significantly lower in the training cohort for
PIK3CA-mutated MSS CC patients as compared with
wild-type PIK3CA MSS CC patients (HR = 0.12; 95% CI,
0.029–0.48; P = 0.0027). Although not significant, a trend
toward decreased recurrence risk was observed for
PIK3CA-mutated MSS CC patients in the validation
cohort (HR = 0.49; 95% CI, 0.23–1.1; P = 0.074), and
PIK3CA mutation variable remained with TNM stage in a
backward–forward step selection to reduce the multivari-
ate model to the only informative variables.
Within the MSI tumors, patients with PIK3CA muta-
tion in the training cohort experienced a significantly
decreased RFI than those without PIK3CA mutation on
univariate analysis (5-year RFI 67% vs. 87%, Log-rank
P = 0.043, HR = 3.4; 95% CI, 0.96–12; P = 0.058) (Fig.
S4A). This finding was not confirmed in the validation
cohort (5-year RFI 100% vs. 80%, Log-rank P = 0.44)
(Fig. S4B).
In the two cohorts, we found that the impact of
PIK3CA mutation was not different between patients with
MSS CC who received adjuvant chemotherapy and those
who had no adjuvant treatment (Fig. S5).
Discussion
Over the past several decades, significant progress has
been achieved in the treatment of CC, mostly due to
improvements in surgical techniques and chemothera-
peutic regimens [31, 32]. These advances have contrib-
uted to increase cancer-specific survival (CSS), but
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Figure 1. Kaplan–Meier curves for relapse-free interval in the CIT cohort (A) and in the Dijon cohort (B), for overall survival in the CIT cohort (C)
and in the Dijon cohort (D) according to PIK3CA status in microsatellite stable tumors.
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patient outcome is still difficult to predict. Thus, prog-
nostic biomarkers are required to guide physicians for
patient management and follow-up after CC curative
resection. Currently, the most recognized prognostic fac-
tor in CRC is the AJCC/UICC TNM staging system,
defined by the depth of bowel wall invasion and by the
presence of metastases in lymph nodes or more distant
sites. However, there remains considerable heterogeneity
in outcome within the different stages of this classifica-
tion [33]. Many studies assessed the potential prognostic
impact of several somatic mutations including KRAS,
BRAF, and TP53 mutations after curative surgery [34–
36]. So far, none of these has been identified as a
reproducible prognostic biomarker, except V600E BRAF
mutation, which seems to be an independent biomarker of
poor prognosis in MSS stage III CCs [37]. Regarding
PI3KCA mutations, reports are scarce and results are equiv-
ocal [16–20]. None used an independent validation group
to support their conclusions. Some of them included
patients with stage IV disease [16, 18, 19], while others
evaluated also patients with rectal cancer [16, 18, 19, 21].
In a series of 418 CRCs, Abubaker and colleagues reported
that PIK3CA mutations were not associated with OS [16].
Day and colleagues found similar results in a series of 585
stage II–III CRC regarding disease-free survival (DFS) [21].
Nevertheless, this finding is in contradiction with other
Table 5. Cox proportional hazards model for RFI among microsatellite stable tumors in the two cohorts.
Variables
Univariate analysis Multivariate analysis1
n n events HR 95% CI P value n HR 95% CI P value
CIT cohort
TNM stage
II 366 99 5.1 0.7–38 0.11 366 5.4 0.74–39 0.096
III 366 99 11 1.5–77 0.019 11 1.5–80 0.017
PIK3CA
Mutated 366 99 0.12 0.029–0.48 0.0029 0.12 0.029–0.48 0.0027
Gender
Male 366 99 1.1 0.73–1.6 0.67
Age
– 365 99 1 0.98–1 0.84
Tumor location
Proximal colon 366 99 1 0.66–1.5 0.99
KRAS
Mutated 363 99 1.2 0.81–1.8 0.37
BRAF
Mutated 323 78 1.5 0.36–6 0.6
CIMP
CIMP+ 310 74 0.98 0.45–2.1 0.95
Dijon cohort
TNM stage
II 327 97 2.5 0.89–6.8 0.084 327 2.5 0.89–6.8 0.084
III 327 97 4.2 1.5–12 0.0058 4.2 1.5–12 0.0058
PIK3CA
Mutated 327 97 0.45 0.21–0.97 0.042 0.49 0.23–1.1 0.074
Gender
Male 327 97 1.1 0.71–1.6 0.77
Age
- 327 97 0.99 0.98–1 0.46
Tumor location
Proximal colon 327 97 0.7 0.44–1.1 0.11
KRAS
Mutated 324 95 1.3 0.86–1.9 0.22
BRAF
Mutated 327 97 0.31 0.043–2.2 0.24
CIMP
CIMP+ 326 97 0.89 0.45–1.8 0.75
CIMP, CpG island methylator phenotype; HR, hazard ratio; CI, confidence interval; P value, Wald test P value.
1Multivariate models include significant variables (P < 0.05).
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publications showing that any PIK3CA mutation induced a
significant decrease in survival [17, 18]. Furthermore, stud-
ies that evaluated disease outcome according to the type of
PIK3CA mutation have led to different conclusions. Fari~na
Sarasqueta and colleagues found that mutations located in
exon 20 conferred poorer survival in stage III patients [20].
But recently, Liao and colleagues emphasized that the prog-
nostic impact of PI3KCA mutations was only restricted to
the small proportion of CRCs harboring concomitant
mutations in both exon 9 and 20 [19]. Finally, in a large
series of 627 stage III CC, Ogino and colleagues found that
PIK3CA mutation was neither a prognostic biomarker nor
a predictive biomarker of response to adjuvant chemother-
apy [22]. It should be noted that these patients have been
enrolled in a randomized controlled trial and received
either the Roswell Park regimen of 5-fluoro-uracil (FU)/
leucovorin (LV) or the regimen of irinotecan/FU/LV. These
adjuvant treatments are, however, not those recommended
in case of stage III disease (i.e., a combination of FU and
oxaliplatin) [38].
We found in the present study that PI3KCA mutations
had a favorable prognostic impact in MSS stage I–III CC.
This finding is based on two large homogenous groups of
patients, excluding those with rectal cancer or distant
metastatic disease. Indeed, prognosis and management of
patients with rectal cancer differ from that of patients
with CC, as neoadjuvant chemoradiotherapy and quality
of surgery have a significant impact on local recurrence
[39, 40]. Moreover, prognostic biomarkers and chemo-
therapy regimens differ greatly between localized and
advanced CC. Especially, targeted therapies can be used
for patients with stage IV CRC, and discussions are still
ongoing as to whether PIK3CA mutations including those
present at the exon 20 are predictive biomarkers of
response to anti-EGFR monoclonal antibodies [41].
Although retrospective, our training cohort showed
quite similar molecular features than those of our pro-
spective validation cohort, either for all patients or for
patients with MSS CC. The mutation rates of PIK3CA,
KRAS, and BRAF were consistent with those reported in
the literature and were obtained from frozen tumoral tis-
sues [2]. In the literature, PIK3CA mutations have been
reported to be significantly more frequent in women [24],
in elderly patients [21], in proximal tumors [21, 24], in
KRAS-mutated tumors, [17, 21, 24] and in MSI tumors
[16]. In contrast with these reports, we did not find a
consistent association between PIK3CA mutations and
one particular clinical or molecular characteristic in our
two cohorts of patients. The fact that the prognostic value
of PIK3CA mutations was not confirmed on multivariate
analysis could be explained by the clinical characteristics
of the patients included in the validation cohort. The
MSS tumors included in this second cohort were
associated with a spontaneous better prognosis with sig-
nificantly less stage III CC and less indications for adju-
vant chemotherapy. One might assume that this group
was underpowered to detect a statistical difference.
Very recently, Liao and colleagues highlighted that the
use of aspirin after diagnosis among patients with
PIK3CA-mutated CRC was associated with a significant
longer CCS and OS compared with patients with
PIK3CA-wild-type CRC, with an 82% reduction in CRC
deaths and a 45% reduction in deaths from all causes
[42]. In this study based on two large prospective com-
bined cohorts, the authors concluded that this gene could
be used as a predictive biomarker for the prescription of
aspirin therapy in adjuvant setting. Similarly, Domingo
and colleagues also found in a large randomized trial
comparing rofecoxib with placebo after primary CRC
resection that regular use of low-dose aspirin after CRC
diagnosis was associated with a reduced rate of recurrence
in patients with PIK3CA-mutated tumors compared with
PIK3CA-wild-type tumors (HR = 0.11; 95% CI; 0.001–
0.832; P = 0.027) [43]. But, in a series of 1487 CRC
patients including 185 patients with PIK3CA-mutated
tumors, Kothari and colleagues did not confirm the rela-
tionship between aspirin use and improved survival in
patients with stage II-III disease [44]. We were not able
to assess patients’ survival according to PIK3CA status
and aspirin treatment since information regarding aspirin
therapy was not available in our database. However,
definitive conclusion about the predictive value of
PIK3CA mutations for aspirin treatment in nonmetastatic
CRC can only be given with the results of a randomized
trial.
The negative prognostic impact of PIK3CA mutations
in MSI CC was not confirmed in the validation cohort.
MSI CRCs have a significantly better prognosis with
higher survival rates compared to MSS CRCs [23]. In
adjuvant setting, this phenotype is associated with a halv-
ing of the risk of recurrence [45]. Therefore, for clinical
practice, effective and accurate biomarkers of disease
relapse after curative surgery are particularly required for
patients with MSS tumors. MSI CRCs also constitute a
heterogeneous group of CC, including both tumors with
germline mutation of mismatch repair genes and tumors
with CIMP and hypermethylation of the MLH1 gene pro-
moter. The two cohorts were too small to analyze the
influence of PIK3CA mutations according to the different
subgroups of MSI tumors.
As for the study of Ogino and colleagues, we found
that PIK3CA mutations were not a predictive biomarker
for response to adjuvant chemotherapy [22]. In our
study, PIK3CA mutation was a good prognostic biomar-
ker, either in patients with MSS CC treated with adjuvant
chemotherapy or those without adjuvant treatment. The
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type of adjuvant chemotherapy regimen was not recorded
in our study, but it seems likely that a majority of
patients received an oxaliplatin-based regimen, as recom-
mended.
Our results seem to be in complete contrast with previ-
ous reports in CRC. Indeed, in experimental models,
PIK3CA gain-of-function mutations have been shown to
cause increased phosphorylation of AKT, aberrant activa-
tion of the PI3K/AKT/mTOR signaling pathway, and to
promote oncogenic transformation. One would expect
that proto-oncogene activation (or tumor suppressor gene
inactivation) would clinically be associated with aggressive
tumor behavior and unfavorable prognosis. However, in
understanding of cancer biology, such reasoning seems
too simplistic and contradicted by the well-known exam-
ple of MSI phenotype in CRC [23]. Finally, the good
prognostic value of PIK3CA mutations has been empha-
sized in other cancer types, such as breast cancer, endo-
metrial cancer, ovarian clear cell carcinoma, and
esophageal squamous cell carcinoma [46–49]. Notably,
Kalinsky and colleagues showed in a series of 509 primary
breast tumors with a median follow-up of more than
12 years that patients with PIK3CA-mutated tumors had
a less aggressive phenotype with a significant improve-
ment in OS and CSS [46]. Similarly, Shigaki and col-
leagues found in a series of 219 patients who had
undergone curative resection of stage I–III esophageal
squamous cell carcinoma that patients with PIK3CA
mutations experienced significantly longer DFS, CSS, and
OS than those with wild-type PIK3CA [49]. One possible
explanation is that PIK3CA mutations could result in
oncogene-induced senescence [46], but the biological
mechanisms underlying this effect are still unclear.
Finally, in CRC, Baba and colleagues reported in a series
of 717 samples that phosphorylated AKT expression was
significantly associated with PIK3CA mutations, and that
patients with AKT-activated tumors had a significantly
improved CSS in multivariate analysis [50]. Surprisingly
in this study, the authors used the data from the Nurses’
Health Study and the Health Professionals Follow-up
Study, which are the same cohorts as those used in the
studies of Ogino and colleagues and Liao and colleagues
that led to diametrically opposite conclusions regarding
the prognostic impact of PIK3CA mutations [17, 19].
In summary, our study suggests that PIK3CA muta-
tions are associated with better outcome in patients with
resected MSS stage I-III CC. Our results may have clinical
implications and provide useful information for the post-
operative management of patients. Those with high-risk
stage II or stage III PIK3CA-mutated MSS CC may not
require adjuvant chemotherapy. Nevertheless, the mecha-
nisms explaining this favorable prognostic impact of
PIK3CA mutations remain to be elucidated. We cannot
exclude that this could be the reflect of the predictive
value of aspirin therapy. These results warrant confirma-
tion in further translational studies.
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Figure S1. Kaplan-Meier curves for relapse-free interval
in the CIT cohort (A) and in the Dijon cohort (B), for
overall survival in the CIT cohort (C) and in the Dijon
cohort (D) according to PIK3CA status in stage I–II
microsatellite stable tumors.
Figure S2. Kaplan-Meier curves for relapse-free interval
in the CIT cohort (A) and in the Dijon cohort (B), for
overall survival in the CIT cohort (C) and in the Dijon
cohort (D) according to PIK3CA status in stage III micro-
satellite stable tumors.
Figure S3. Kaplan-Meier curves for relapse-free interval
in the CIT cohort (A) and in the Dijon cohort (B),
according to PIK3CA exon-specific mutation in microsa-
tellite stable tumors.
Figure S4. Kaplan-Meier curves for relapse-free interval
in the CIT cohort (A) and in the Dijon cohort (B), fac-
cording to PIK3CA status in microsatellite instable
tumors.
Figure S5. Kaplan-Meier curves for relapse-free interval
according to PIK3CA status in microsatellite stable
tumors for patients operated on without adjuvant che-
mothrapy in the CIT cohort (A) and in the Dijon cohort
(D), and for those treated with adjuvant chemotherapy in
the CIT cohort (B) and in the Dijon cohort (D).
382 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PIK3CA Mutations in Microsatellite Stable Colon Cancer G. Manceau et al.
